Edition:
United Kingdom

Grifols SA (GRLSbn.MC)

GRLSbn.MC on Madrid SE C.A.T.S.

18.68EUR
20 Feb 2018
Change (% chg)

€0.36 (+1.97%)
Prev Close
€18.32
Open
€18.44
Day's High
€18.72
Day's Low
€18.44
Volume
38,801
Avg. Vol
75,411
52-wk High
€20.65
52-wk Low
€16.00

Select another date:

Tue, Feb 6 2018

BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment

* GRIFOLS HYPERRAB® (RABIES IMMUNE GLOBULIN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US Assets

* SEES POSITIVE NON-RECURRING IMPACT OF ABOUT 90 MILLION EUROS NET IN Q4 FROM US TAX REFORM AND REASSESSMENT OF ASSETS RELATED TO ARADIGM Source text for Eikon:

BRIEF-Grifols Buys 51 Pct Of Medkeeper

* SAYS PURCHASE RESULT OF $98 MLN CAPITAL INCREASE IN MEDKEEPER

BRIEF-Grifols Gets Loan With EIB For 85 Mln Euros

* GETS LONG-TERM LOAN WITH THE EUROPEAN INVESTMENT BANK (EIB) FOR 85 MILLION EUROS

BRIEF-Grifols gets approval from US FDA for new product

* EARNS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR NEW PRODUCT FIBRIN SEALANT (HUMAN) COMPOSED OF TWO PLASMA PROTEINS AND INDICATED FOR SURGICAL USE IN ADULTS ‍​ Source text for Eikon:

BRIEF-Grifols 9-month net profit up 6.3 pct at 431.8 mln euros YoY

* 9-MONTH NET PROFIT 431.8 MILLION EUROS VERSUS 406.1 MILLION EUROS YEAR AGO

BRIEF-Grifols approves interim dividend of 0.18 eur/shr

* APPROVES INTERIM DIVIDEND OF 0.18 EURO PER SHARE PAYABLE DECEMBER 5‍​ Source text for Eikon:

Spain's Grifols to remain in Catalonia for now - source

MADRID Spain's Grifols has no plans to leave Catalonia at the moment but, if the current situation changes in a way which could affect the company's business, the board will take appropriate steps, a company sources said on Monday.

Spain's Grifols to remain in Catalonia for now -source

MADRID, Oct 9 Spain's Grifols has no plans to leave Catalonia at the moment but, if the current situation changes in a way which could affect the company's business, the board will take appropriate steps, a company sources said on Monday. (Reporting by Emma Pinedo; Writing by Paul Day; Editing by Jesus Aguado)

BRIEF-Grifols gets FDA approval for Prolastin-C

* SAYS GETS APPROVAL FROM FDA (US FOOD AND DRUG ADMINISTRATION) FOR PROLASTIN-C LIQUID AS A REPLACEMENT THERAPY‍​ TO TREAT RARE GENETIC DISORDER

Select another date: